Comparison of an Non-ablative Fractional 1565nm vs. an Ablative 2940-nm Fractional Er Laser for the Treatment of Androgenetic Alopecia

Last updated: January 21, 2024
Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University
Overall Status: Active - Recruiting

Phase

N/A

Condition

Alopecia

Hair Loss

Male Pattern Baldness

Treatment

non-ablative fractional 1565nm

ablative fractional 2940-nm Er: YAG laser

5% Minoxidil

Clinical Study ID

NCT06218498
20230943
  • Ages 18-65
  • Male

Study Summary

Laser sources have established their potential effect in inducing hair regrowth. No study has compared the effect of ablative fractional 2940-nm erbium yttrium aluminum garnet (Er: YAG) laser and non-fractional 15650nm fractional laser in the treatment of androgenetic alopecia (AGA).

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • age between 18 and 65 years;;
  • clinical diagnosis of AGA;
  • AGA diagnosis was evaluated following Norwood Hamilton grade II-V criteria;
  • no previous laser treatments for AGA in the past six months before enrollment;
  • willingness to provide pictures and follow-up studies.

Exclusion

Exclusion Criteria:

  • if presented with severe diseases of internal organs, eyes, or skin;
  • inflammation, infection, or unhealed wounds on the skin around the site of treatmenton the head;
  • systematic treatment with corticosteroids or other immunosuppressants andimmunomodulators in the past 3 months

Study Design

Total Participants: 135
Treatment Group(s): 3
Primary Treatment: non-ablative fractional 1565nm
Phase:
Study Start date:
November 24, 2023
Estimated Completion Date:
December 31, 2024

Study Description

The investigators performed a prospective study between to compare the efficacy and safety of ablative fractional 2940-nm erbium yttrium aluminum garnet (Er: YAG) laser and non-fractional 15650nm fractional laser in the treatment of androgenetic alopecia (AGA). The efficacy of the two therapies was evaluated by the investigator's Global Assessment (IGA) scores and the patient's Likert satisfaction scale at week 12 and week 24. Changes in total, terminal and villous hair count, total and terminal hair diameter, and AGA grade were also recorded. Adverse events were evaluated at each follow-up.

Connect with a study center

  • Second Affiliated Hospital, School of Medicine, Zhejiang University, China

    Hangzhou, Zhejiang 310009
    China

    Active - Recruiting

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.